PHARMACOKINETICS OF ORAL AND INTRAVENOUS MELPHALAN DURING ROUTINE TREATMENT OF MULTIPLE-MYELOMA

被引：79

作者：

BOSANQUET, AG ^{[1
]}

GILBY, ED ^{[1
]}

机构：

[1] ROYAL UNITED HOSP,DEPT MED ONCOL,BATH BA1 3NG,AVON,ENGLAND

来源：

EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY | 1982年 / 18卷 / 04期

关键词：

D O I：

10.1016/0277-5379(82)90006-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：355 / 362

页数：8

共 29 条

[1]

ALBERTS DS, 1979, CLIN PHARMACOL THER, V26, P73

[2]

ALBERTS DS, 1979, CLIN PHARMACOL THER, V26, P737

[3]

ALEXANIAN R, 1968, BLOOD, V31, P1

[4]

BEGLEITER A, 1979, CANCER RES, V39, P353

[5]

BERGEL F, 1954, J CHEM SOC, V76, P2409

[6]

BOSANQUET AG, UNPUB J CHROMATOGR

[7] PHARMACOLOGY OF INTRAVENOUS MELPHALAN IN PATIENTS WITH MULTIPLE-MYELOMA [J].

BROX, L ;

BIRKETT, L ;

BELCH, A .

CANCER TREATMENT REVIEWS, 1979, 6 :27-32

[8] HIGH-PRESSURE LIQUID-CHROMATOGRAPHIC ANALYSIS OF MELPHALAN IN PLASMA [J].

CHANG, SY ;

ALBERTS, DS ;

MELNICK, LR ;

WALSON, PD ;

SALMON, SE .

JOURNAL OF PHARMACEUTICAL SCIENCES, 1978, 67 (05) :679-682

[9] PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].

COCKCROFT, DW ;

GAULT, MH .

NEPHRON, 1976, 16 (01) :31-41

[10]

CURRY SH, 1977, DRUG DISPOSITION PHA

← 1 2 3 →